Prentiss Smith & Co’s GSK GSK Stock Holding History

Prentiss Smith & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-374	Closed	-$19K	–	128
2018 Q3	$19K	Sell	374 -400	-52%	-$20.3K	0.01%	171
2018 Q2	$39K	Hold	774	–	–	0.02%	133
2018 Q1	$38K	Buy	+774	New	+$36K	0.02%	137
2017 Q4	–	Sell	-774	Closed	-$39K	–	308
2017 Q3	$39K	Buy	+774	New	+$39.3K	0.02%	125

Other funds holding GSK

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BCIM

Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return

Prentiss Smith & Co's GSK Position: Q4 2018 in Review

Prentiss Smith & Co sold out of GSK (GSK) in Q4 2018, closing a stake of 374 shares — an estimated $19K sold.

Prentiss Smith & Co first reported a position in GSK in Q3 2017 and held it in 4 quarters. The position peaked at $39K in Q2 2018. 800 funds tracked by Wall St. Rank hold GSK as of Q4 2018.

Prentiss Smith & Co reported no remaining GSK position as of Q4 2018 after selling out during the quarter.
Prentiss Smith & Co sold 374 GSK shares in Q4 2018, an estimated $19K.
Prentiss Smith & Co first reported a position in GSK in Q3 2017 and held it in 4 quarters.
Prentiss Smith & Co's GSK position peaked at $39K in Q2 2018.
800 funds tracked by Wall St. Rank held GSK as of Q4 2018.

Based on Prentiss Smith & Co's 13F filing for Q4 2018, filed 15 Jan 2019.